On July 13, 2020 Helix BioPharma Corp. (TSX: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, reported that, further to its news release dated June 11, 2020, it intends to file its interim consolidated financial statements for the three and nine month periods ended April 30, 2020, related management’s discussion and analysis ("MD&A") and related management certifications (the "Interim Disclosure Documents") by July 30, 2020 (Press release, Helix BioPharma, JUL 13, 2020, View Source [SID1234561824]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!